|
|
|
Two different chemical agents, one associated with Alzheimer's, the other with a severe lung disease, cause inflammation in the same way, reports two studies published online in Nature Immunology. This finding could provide a therapeutic target for the treatment of these diseases.
Many structurally diverse molecules, including bacterial toxins and various crystals such as silicon dioxide that cause silicosis in the lungs, induce inflammation by activating a protein complex inside cells called the inflammasome. Groups led by Eicke Latz and Douglas Golenbock show that silicon dioxide crystals and the form of beta-amyloid protein linked to Alzheimer's disease are taken up by cells in a way that produces inflammation. This process involves seepage of the cathepsin B protein from compartments called lysosomes, which destroy cellular debris. The release of cathepsin B triggers the uncontrolled immune responses associated with silicosis and Alzheimer's disease. Characterizing this signalling cascade, which is very likely to be associated with other inflammatory diseases such as gout, may thus provide a common target for treatment of a myriad of conditions. Author contacts: Eicke Latz (University of Massachusetts Medical School, Worcester, MA, USA)
E-mail: eicke.latz@umassmed.edu Douglas Golenbock (University of Massachusetts Medical School, Worcester, MA, USA)
E-mail: douglas.golenbock@umassmed.edu Abstracts available online:
Abstract 1.
Abstract 2 (C) Nature Immunology press release.
Message posted by: Trevor M. D'Souza
|
|
Variants Associated with Pediatric Allergic Disorder
Mutations in PHF6 Found in T-Cell Leukemia
Genetic Risk Variant for Urinary Bladder Cancer
Antibody Has Therapeutic Effect on Mice with ALS
Regulating P53 Activity in Cancer Cells
Anti-RNA Therapy Counters Breast Cancer Spread
Mitochondrial DNA Diversity
The Power of RNA Sequencing
‘Pro-Ageing' Therapy for Cancer?
Niche Genetics Influence Leukaemia
Molecular Biology: Clinical Promise for RNA Interference
Chemoprevention Cocktail for Colon Cancer
more news ...
|